NEW YORK (GenomeWeb News) - GVK Biosciences today said it has inked an agreement that will give the US Food and Drug Administration access to the company’s Clinical Biomarker Database.
Under the agreement, the FDA will use the database as part of its Voluntary Exploratory Data Submission Program and in internal research projects.
The database holds information from published literature relating to clinical and pre-clinical biomarkers, and may be used in biomarker design and validation research, the company said.
GVK Bio, which is headquartered in Hyderabad, India, has a US base in Columbia, Md.
Financial terms of the agreement were not released.